TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TYK Medicines, Inc. Class H ( (HK:2410) ) just unveiled an update.
TYK Medicines, Inc reported a significant reduction in its total comprehensive loss for the first half of 2025 compared to the same period in 2024, with a decrease from RMB 219.5 million to RMB 114.1 million. This improvement is primarily attributed to a substantial reduction in research and development costs by 35.6%, although the company still reported no revenue and continued to face administrative and finance costs.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on research and development, as indicated by its significant expenditure in this area, and is listed on the Stock Exchange of Hong Kong Limited.
Average Trading Volume: 5,874,820
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.51B
See more insights into 2410 stock on TipRanks’ Stock Analysis page.